ArticleFrontiers in oncology2026
Case Report: Prostate metastasis from pulmonary sarcomatoid carcinoma: the first reported case and clinical implications of palliative radiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary sarcomatoid carcinoma (PSC) is a highly aggressive lung cancer subtype. Prostate metastasis is extremely rare in lung cancer, and no PSC case with immunohistochemical confirmation has been reported. We report a 68-year-old man diagnosed with left upper lobe carcinosarcoma (myogenic differentiation) on pathological biopsy. He underwent multimodal treatment, including radical resection, adjuvant chemotherapy, anlotinib targeted therapy, and local thoracic radiotherapy. Eight months later, he developed progressive dysuria. Whole-body positron emission tomography-computed tomography (PET-CT) showed hypermetabolic lesions in the prostate and multiple systemic sites, while the serum prostate-specific antigen (PSA) level remained normal. Transurethral resection of the prostate (TURP) was performed, and pathology confirmed metastatic sarcomatoid carcinoma. Palliative radiotherapy to the prostate (62.5 Gy/25 fractions) completely resolved his urinary symptoms. The patient died 11 months after diagnosis from pulmonary infection. This is the first documented case of prostate metastasis from PSC worldwide. For such patients, histopathological and immunohistochemical confirmation is indispensable, and palliative radiotherapy can effectively relieve urinary symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.